Advanced in Primary Lymphoma of the Brain

Dr. Tulika Ranjan

Neurology | Oncology
Mary Hitchcock Memorial Hospital
1 Medical Ctr Dr, 
Lebanon, NH 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Advanced in Primary Lymphoma of the Brain
Mary Hitchcock Memorial Hospital
1 Medical Ctr Dr, 
Lebanon, NH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Tulika Ranjan is a Neurologist and an Oncologist in Lebanon, New Hampshire. Dr. Ranjan is rated as an Advanced provider by MediFind in the treatment of Primary Lymphoma of the Brain. Her top areas of expertise are Astrocytoma, Glioblastoma, Glioma, and Brain Tumor. Dr. Ranjan is currently accepting new patients.

Her clinical research consists of co-authoring 12 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Neurology
Oncology
Licenses
Internal Medicine in FL
Hospital Affiliations
Mary Hitchcock Memorial Hospital
Languages Spoken
English
Hindi
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
NH Healthy Families
  • EPO
  • MANAGED MEDICAID PLAN
Oscar
  • EPO
  • HMO
  • PPO
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

MARY HITCHCOCK MEMORIAL HOSPITAL
1 Medical Ctr Dr, Lebanon, NH 03756

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM
GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM
Enrollment Status: Recruiting
Publish Date: September 09, 2025
Intervention Type: Drug, Radiation, Biological
Study Drugs: Temozolomide, Lomustine, Regorafenib, Paxalisib, VAL-083
Study Phase: Phase 2/Phase 3
Standard Chemotherapy Versus Chemotherapy Chosen by Cancer Stem Cell Chemosensitivity Testing in the Management of Patients With Recurrent Glioblastoma Multiforme (GBM).
Standard Chemotherapy Versus Chemotherapy Chosen by Cancer Stem Cell Chemosensitivity Testing in the Management of Patients With Recurrent Glioblastoma Multiforme (GBM).
Enrollment Status: Completed
Publish Date: April 15, 2025
Intervention Type: Diagnostic test, Drug
Study Phase: Phase 3
Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Enrollment Status: Active_not_recruiting
Publish Date: August 02, 2024
Intervention Type: Drug, Radiation
Study Drugs: Concomitant Temozolomide (TMZ), Procarbazine, Adjuvant Temozolomide (TMZ), CCNU, Vincristine
Study Phase: Phase 3
A Randomized, Placebo Controlled Phase 3 Study of ABT-414 With Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)
A Randomized, Placebo Controlled Phase 3 Study of ABT-414 With Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)
Enrollment Status: Completed
Publish Date: May 11, 2023
Intervention Type: Drug, Radiation
Study Drugs: Temozolomide, Depatuxizumab
Study Phase: Phase 3
View 3 Less Clinical Trials

12 Total Publications

Emerging Therapies for Brain Metastases in NSCLC, Breast Cancer, and Melanoma: A Critical Review.
Emerging Therapies for Brain Metastases in NSCLC, Breast Cancer, and Melanoma: A Critical Review.
Journal: Current neurology and neuroscience reports
Published: October 19, 2024
Similar Doctors
Distinguished in Primary Lymphoma of the Brain
Dr. David J. Ospina
Hematology Oncology | Oncology | Hematology
Distinguished in Primary Lymphoma of the Brain
Dr. David J. Ospina
Hematology Oncology | Oncology | Hematology

Central Vermont Medical Center Inc

130 Fisher Rd, Suite 1 2, 
Berlin, VT 
 (40.3 miles away)
802-225-5400
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

David Ospina is a Hematologist Oncology specialist and an Oncologist in Berlin, Vermont. Dr. Ospina is rated as a Distinguished provider by MediFind in the treatment of Primary Lymphoma of the Brain. His top areas of expertise are Primary Lymphoma of the Brain, Paget Disease of the Breast, Richter Syndrome, Chronic Lymphocytic Leukemia (CLL), and Bone Marrow Aspiration. Dr. Ospina is currently accepting new patients.

Advanced in Primary Lymphoma of the Brain
Dr. Frederick N. Lansigan
Hematology Oncology | Hematology | Oncology
Advanced in Primary Lymphoma of the Brain
Dr. Frederick N. Lansigan
Hematology Oncology | Hematology | Oncology

Dartmouth-Hitchcock Clinic

1 Medical Ctr Dr, 
Lebanon, NH 
 (0.1 miles away)
603-650-5000
Languages Spoken:
English
See accepted insurances

Frederick Lansigan is a Hematologist Oncology specialist and a Hematologist in Lebanon, New Hampshire. Dr. Lansigan is rated as an Elite provider by MediFind in the treatment of Primary Lymphoma of the Brain. His top areas of expertise are Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia (CLL), Cutaneous T-Cell Lymphoma (CTCL), Bone Marrow Aspiration, and Bone Marrow Transplant.

Experienced in Primary Lymphoma of the Brain
Dr. Amandeep Kalra
Neurology | Oncology | Hematology Oncology
Experienced in Primary Lymphoma of the Brain
Dr. Amandeep Kalra
Neurology | Oncology | Hematology Oncology

Mary Hitchcock Memorial Hospital

1 Medical Ctr Dr, 
Lebanon, NH 
 (0.1 miles away)
603-650-5000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Amandeep Kalra is a Neurologist and an Oncologist in Lebanon, New Hampshire. Dr. Kalra is rated as a Distinguished provider by MediFind in the treatment of Primary Lymphoma of the Brain. His top areas of expertise are Astrocytoma, Glioblastoma, Oligodendroglioma, and Ependymoma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ranjan's expertise for a condition
ConditionClose
View All 12 Distinguished Conditions
View All 34 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile